Search - tctmd.com

Displaying 621 - 640 of 1865

Sort: Relevancy | Date

Presentation ARCH 2019

Update on Dual Antiplatelet Therapy

Presenter: James B Hermiller

April 12, 2019

News Daily News

Baseline Anemia Ups Physician-Guided DAPT Discontinuation Rates After PCI

Yael L. Maxwell

April 10, 2019

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2019

Shelley Wood

March 29, 2019

Presentation SIF 2019

DAPT Duration and When to Switch to Antiplatelet Monotherapy Post PCI

Presenter: Michael A. Kutcher

March 28, 2019

Presentation CIT 2019

Global Leaders and Glassy

Presenter: Patrick W. Serruys

March 28, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Opinion Editor's Corner ACC 2019

Live From New Orleans: Days 2 and 3 at ACC 2019

Shelley Wood

March 18, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

Presentation OPCI 2019

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

Presenter: Roxana Mehran

March 09, 2019

News Daily News

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

Shelley Wood

March 08, 2019

News Conference News CRT 2019

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Yael L. Maxwell

March 04, 2019

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

News Conference News ISC 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

Todd Neale

February 12, 2019

Advertisement

Update on Dual Antiplatelet Therapy

Baseline Anemia Ups Physician-Guided DAPT Discontinuation Rates After PCI

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

TCTMD’s Top 10 Most Popular Stories for March 2019

DAPT Duration and When to Switch to Antiplatelet Monotherapy Post PCI

Global Leaders and Glassy

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Live From New Orleans: Days 2 and 3 at ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Optimal Duration of Antiplatelet Therapy – Does IV Imaging Make A Difference?

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content